Bank Of America Corp Eiger Bio Pharmaceuticals, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.21 - $0.43 $481 - $986	-2,295 Reduced 4.55%	48,121 $10,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $3,810 - $8,730	-6,929 Reduced 12.08%	50,416 $35,000
Q1 2023 May 12, 2023	BUY	$0.89 - $2.52 $9,585 - $27,140	10,770 Added 23.12%	57,345 $51,000
Q4 2022 Feb 10, 2023	BUY	$1.02 - $7.48 $33,732 - $247,371	33,071 Added 244.9%	46,575 $54,000
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $28,418 - $45,450	-4,705 Reduced 25.84%	13,504 $103,000
Q2 2022 Aug 12, 2022	SELL	$4.99 - $8.96 $21,362 - $38,357	-4,281 Reduced 19.04%	18,209 $114,000
Q1 2022 May 16, 2022	SELL	$3.84 - $9.74 $30,973 - $78,562	-8,066 Reduced 26.4%	22,490 $187,000
Q4 2021 Feb 08, 2022	BUY	$5.12 - $8.19 $59,745 - $95,569	11,669 Added 61.78%	30,556 $159,000
Q3 2021 Nov 15, 2021	SELL	$6.68 - $9.1 $14,281 - $19,455	-2,138 Reduced 10.17%	18,887 $126,000
Q2 2021 Sep 13, 2021	BUY	$7.82 - $9.23 $164,415 - $194,060	21,025 New	21,025 $180,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.